CoChat

Role of Colesevelam in Combination Lipid-Lowering Therapy

Open access
Jones, Michael R., Nwose, Oliseyenum M. · 2013 · American Journal of Cardiovascular Drugs

The DOI matches its Crossref record; 76 of the 78 references it cites were found in a registry or an index.

Abstract

Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a mortality benefit related to LDL-C lowering, statins are now considered first-line pharmacological therapy for reducing LDL-C levels because of their potency and their remarkable record of successful outcomes studies. Nevertheless, a substantial proportion of patients do not achieve LDL-C goals with statin monotherapy. In addition, because of adverse effects (primarily myopathy), some patients may be unwilling to use or unable to tolerate statin therapy at all or may not tolerate a full therapeutic statin dose. Also, statins may increase risk of new-onset diabetes in patients at high risk for diabetes. Thus, there remains a need for other lipid-lowering drugs to be used in combination with or in place of statins. The purpose of this article is to review available data from the literature on the use of colesevelam, a second-generation bile acid sequestrant, in combination with other lipid-lowering agents. Colesevelam has been studied in combination with statins, niacin, fibrates, and ezetimibe (including some three-drug combinations). An additive reduction in LDL-C was seen with all combinations. Other observed effects of colesevelam in combination with other lipid-lowering drugs include reductions in apolipoprotein (apo) B (with statins, fibrates, ezetimibe, statin plus niacin, or statin plus ezetimibe) and high-sensitivity C-reactive protein (with statins), and increases in apo A-I (with statins, ezetimibe, or statins plus niacin). Triglyceride levels remained relatively unchanged when colesevelam was combined with statins, fibrates, ezetimibe, or statin plus ezetimibe, and decreased with the triple combination of colesevelam, statin, and niacin. Colesevelam offset the negative glycemic effects of statins and niacin in subjects with insulin resistance or impaired glucose tolerance. Colesevelam was generally well tolerated when added to other lipid-lowering therapies in clinical trials, with gastrointestinal effects such as constipation being the predominant adverse events. Since colesevelam is not absorbed and works primarily in the intestine, it has a low potential for systemic metabolic drug-drug interactions with other drugs. Colesevelam has been shown to not interact with the lipid-lowering drugs lovastatin and fenofibrate; where interaction may be anticipated, separating dosing times by 4 h reduces the impact of any interaction. Available data confirms that colesevelam has additive cholesterol-lowering effects when used in combination with other lipid-lowering therapies. Furthermore, in some patient populations, the additional glucose-lowering effect of colesevelam may be beneficial in offsetting hyperglycemic effects of other lipid-lowering drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40256-013-0037-0

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Percent reductions from baseline in low-density lipoprotein cholesterol (LDL-C) in studies evaluating colesevelam (COL) administered in combination with a statin: a COL and atorvastatin (ATO) alone and in combination [41], b COL and lovastatin (LOV) alone and in combination [40], and c COL and simvastatin (SIM) alone and in combination [42]. a p < 0.01 for all between-group comparisons. b p < 0.01 for all between-group comparisons except COL + ATO 10 mg/day vs. ATO 80 mg/day (p = 0.07). c p < 0.05 vs. placebo. d p < 0.05 vs. each monotherapy. e p < 0.0001 vs. placebo. f p ≤ 0.001 vs. each monotherapy. gCOL and LOV given together at dinner. hCOL given at dinner and LOV administered at bedtime. ATO panel adapted from Hunninghake et al. [41], with permission from Elsevier. LOV panel reproduced from Davidson et al. [40], Copyright © 2001 Wiley Periodicals, Inc., with permission from John Wiley & Sons, Inc. SIM panel adapted from Knapp et al. [42], with permission from Elsevier
Fig. 1 Percent reductions from baseline in low-density lipoprotein cholesterol (LDL-C) in studies evaluating colesevelam (COL) administered in combination with a statin: a COL and atorvastatin (ATO) alone and in combination [41], b COL and lovastatin (LOV) alone and in combination [40], and c COL and simvastatin (SIM) alone and in combination [42]. a p < 0.01 for all between-group comparisons. b p < 0.01 for all between-group comparisons except COL + ATO 10 mg/day vs. ATO 80 mg/day (p = 0.07). c p < 0.05 vs. placebo. d p < 0.05 vs. each monotherapy. e p < 0.0001 vs. placebo. f p ≤ 0.001 vs. each monotherapy. gCOL and LOV given together at dinner. hCOL given at dinner and LOV administered at bedtime. ATO panel adapted from Hunninghake et al. [41], with permission from Elsevier. LOV panel reproduced from Davidson et al. [40], Copyright © 2001 Wiley Periodicals, Inc., with permission from John Wiley & Sons, Inc. SIM panel adapted from Knapp et al. [42], with permission from ElsevierCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Research works printed but not linked: 1

  1. Davidson MH, Rooney M, Pollock EM, Drucker JL, Choy Y. The effect of colesevelam and niacin on low-density lipoprotein cholesterol and plasma glucose (abstr.). Circulation. 2012;126(21 Suppl):A11700.

Cited by

See all 31

Metadata

Authors
Jones, M. R., & Nwose, O. M.
Affiliations
Daiichi-Sankyo (Japan) (JP)
Corresponding author
Nwose, Oliseyenum M.
Venue
American Journal of Cardiovascular Drugs
Published
2013-08-03
Volume
13
Issue
5
Pages
315-323
ISSN
  • 1175-3277 (ISSN-L)
  • 1179-187X
OpenAlex
W2021668065
Cited by
27
References
78
Citations by year
2023: 1 · 2022: 3 · 2021: 4 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 5 · 2014: 6
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
colesevelam, bile acid sequestrants, combination lipid-lowering therapy, LDL cholesterol lowering, statins, ezetimibe, nicotinic acid, fibrates, apolipoprotein B, apolipoprotein A-I, high-sensitivity C-reactive protein, triglycerides, statin-induced diabetes, statin-induced myopathy, insulin resistance, impaired glucose tolerance, drug-drug interactions
MeSH terms
Colesevelam Hydrochloride, Allylamine, Anticholesteremic Agents, Drug Interactions, Drug Therapy, Combination, Humans, Hyperlipidemias, Cholesterol, LDL

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Colesevelam in Combination Lipid-Lowering Therapy. https://app.cochat.ai/papers/10.1007/s40256-013-0037-0
The paper
Jones, M. R., & Nwose, O. M. (2013). Role of Colesevelam in Combination Lipid-Lowering Therapy. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-013-0037-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.